Kenvue

Kenvue helps families handle minor health issues like pain, allergies, and skin care. It makes well-known products that people use every day in their homes. These items help individuals stay comfortable and take care of their personal hygiene.

What's on the Shelf?

• Self Care: Over-the-counter medicines for pain, cough, cold, and allergy symptoms including brands like Tylenol and Zyrtec.
• Skin Health and Beauty: Science-backed dermatological solutions and hair care products under names such as Neutrogena and Aveeno.
• Essential Health: Daily personal care items like Listerine mouthwash, Band-Aid bandages, and baby care supplies.

A New Path Forward

• Completed the separation from Johnson & Johnson in August 2023 to become a fully independent public company.
• Entered into a merger agreement with Kimberly-Clark Corporation in November 2025 to combine the two businesses.
• Received shareholder approval for the Kimberly-Clark transaction in January 2026.
• Launched a restructuring initiative called Our Vue Forward to improve organizational efficiency and fuel brand investment.

The Kenvue Difference

The company operates a massive global network, selling products in more than 165 countries. Its internal manufacturing footprint produces roughly 60% of its sales volume, providing flexibility across its diverse brands.

By the Numbers

• Net sales reached $15.1 billion for the fiscal year ended December 28, 2025.
• Operating income rose to $825 million in Q4 2025, a 70.8% increase compared to the previous year.
• Net income grew 12.6% year-over-year to reach $330 million in Q4 2025.
• Free cash flow—the money left after paying for operations and equipment—hit $744 million in Q4 2025, up 12.6% from Q4 2024.

Bottom Line

Kenvue has transitioned from a division of a larger corporation to an independent leader in consumer health. The company is now moving toward a significant combination with Kimberly-Clark to further scale its global household brands.